Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy
Source abstract
Abstract
Immunomodulatory therapeutics, which is conducive to overcoming tumor tolerance and restoring normal immune responses, has been proposed as a promising approach for enhanced cancer therapy and clinical advancement. However, issues including cytokine syndrome, inefficient delivery, hepatic dysfunction, and severe adverse reactions remain to be resolved. It is particularly critical to develop delivery technologies to overcome these limitations and further improve antitumor efficacy. With the continuous development of materials science, biomaterials have been widely used in the field of cancer treatment and have also provided exciting solutions to overcome the bottleneck of immunomodulatory therapeutics. A range of biomaterials, especially nanomaterials, has been developed as a local immunomodulatory platform to enhance targeted delivery, maintain drug stability, and reduce toxicity and side effects. In addition to single immunomodulatory therapeutics, nanomaterials have been demonstrated to possess significant potential in immunomodulatory therapeutics-based synergistic therapies, especially in combination with phototherapy, radiotherapy, chemotherapy, and immune checkpoint blockade. In this review, as background to the discussion of immunomodulatory therapeutics, we first described the mechanisms of action of multiple immunomodulators and discussed their current targeting agents. On this basis, we highlighted the latest advances in the use of nanomaterials-assisted immunomodulatory therapeutics and combination therapy to enhance anticancer immunity. In addition, current challenges and further promises for immunomodulatory therapeutics were also presented.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Marine Life Science, Ocean University of China, Qingdao 266003, P.R. China
Qingdao National Laboratory for Marine Science and Technology, Qingdao 266000, P.R. China
Funding
Shandong Province · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1002/adhm.20180042410.1002/adhm.201800424 ↗
2. 10.1038/nrclinonc.2016.2510.1038/nrclinonc.2016.25 ↗
3. 10.1126/science.aar671110.1126/science.aar6711 ↗
4. 10.1016/j.cell.2017.01.01610.1016/j.cell.2017.01.016 ↗
5. 10.1038/nrc.2016.3610.1038/nrc.2016.36 ↗
6. 10.3389/fphar.2017.0056110.3389/fphar.2017.00561 ↗
7. 10.1038/nm110010.1038/nm1100 ↗
8. 10.3390/vaccines302034410.3390/vaccines3020344 ↗
9. 10.4161/hv.2656810.4161/hv.26568 ↗
10. 10.1038/nrc323910.1038/nrc3239 ↗
11. 10.1126/science.120348610.1126/science.1203486 ↗
12. 10.1126/science.aaa620410.1126/science.aaa6204 ↗
13. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
14. 10.1038/bjc.2017.43410.1038/bjc.2017.434 ↗
15. 10.1016/j.csbj.2015.03.00810.1016/j.csbj.2015.03.008 ↗
16. 10.1016/j.abb.2013.02.00710.1016/j.abb.2013.02.007 ↗
17. 10.1126/scitranslmed.300363410.1126/scitranslmed.3003634 ↗
18. 10.1038/ni75910.1038/ni759 ↗
19. 10.1146/annurev-immunol-030409-10124310.1146/annurev-immunol-030409-101243 ↗
20. 10.1038/nri114810.1038/nri1148 ↗
21. 10.1038/nm.432110.1038/nm.4321 ↗
22. 10.1016/j.addr.2017.05.01110.1016/j.addr.2017.05.011 ↗
23. 10.1038/s41467-017-02251-310.1038/s41467-017-02251-3 ↗
24. 10.1021/nn305466z10.1021/nn305466z ↗
25. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
26. 10.1177/153537021664712310.1177/1535370216647123 ↗
27. 10.1016/j.ejca.2015.09.02610.1016/j.ejca.2015.09.026 ↗
28. 10.1158/0008-5472.CAN-14-253810.1158/0008-5472.CAN-14-2538 ↗
29. 10.1021/acsbiomaterials.9b0198710.1021/acsbiomaterials.9b01987 ↗
30. 10.1080/08830185.2016.126131810.1080/08830185.2016.1261318 ↗
31. 10.1016/S1097-2765(00)80136-710.1016/S1097-2765(00)80136-7 ↗
32. 10.1016/j.imbio.2016.06.00910.1016/j.imbio.2016.06.009 ↗
33. 10.1080/2162402X.2016.123057810.1080/2162402X.2016.1230578 ↗
34. 10.1158/0008-5472.CAN-10-125110.1158/0008-5472.CAN-10-1251 ↗
35. 10.1016/S0167-5699(98)01265-110.1016/S0167-5699(98)01265-1 ↗
36. 10.1016/S0161-5890(00)00079-110.1016/S0161-5890(00)00079-1 ↗
37. 10.1080/14712598.2020.171308410.1080/14712598.2020.1713084 ↗
38. 10.1158/1078-0432.CCR-12-206410.1158/1078-0432.CCR-12-2064 ↗
39. 10.1126/science.119844310.1126/science.1198443 ↗
40. 10.4161/onci.2303310.4161/onci.23033 ↗
41. 10.1016/j.bbcan.2018.12.00210.1016/j.bbcan.2018.12.002 ↗
42. 10.1111/j.1600-065X.2011.01063.x10.1111/j.1600-065X.2011.01063.x ↗
43. 10.1016/j.jaut.2018.08.00710.1016/j.jaut.2018.08.007 ↗
44. 10.1038/nm0697-68210.1038/nm0697-682 ↗
45. 10.1016/j.jtho.2016.01.01310.1016/j.jtho.2016.01.013 ↗
46. 10.1016/j.jss.2011.03.06710.1016/j.jss.2011.03.067 ↗
47. 10.1016/j.ejca.2015.08.02110.1016/j.ejca.2015.08.021 ↗
48. 10.1182/blood-2017-07-74102510.1182/blood-2017-07-741025 ↗
49. 10.4049/jimmunol.164.4.216010.4049/jimmunol.164.4.2160 ↗
50. 10.1158/0008-5472.CAN-10-136910.1158/0008-5472.CAN-10-1369 ↗
51. 10.1002/eji.20114170010.1002/eji.201141700 ↗
52. 10.1172/JCI6485910.1172/JCI64859 ↗
53. 10.4049/jimmunol.165.9.503510.4049/jimmunol.165.9.5035 ↗
54. 10.1016/j.coi.2010.01.00110.1016/j.coi.2010.01.001 ↗
55. 10.4049/jimmunol.100173010.4049/jimmunol.1001730 ↗
56. 10.1371/journal.pone.021944910.1371/journal.pone.0219449 ↗
57. 10.4049/jimmunol.180.2.77410.4049/jimmunol.180.2.774 ↗
58. 10.1080/14712598.2020.169354010.1080/14712598.2020.1693540 ↗
59. 10.1016/j.ymthe.2019.07.01310.1016/j.ymthe.2019.07.013 ↗
60. 10.1080/14728222.2018.151258810.1080/14728222.2018.1512588 ↗
61. 10.1016/j.ejca.2016.06.02810.1016/j.ejca.2016.06.028 ↗
62. 10.1084/jem.2005094010.1084/jem.20050940 ↗
63. 10.1371/journal.pone.001043610.1371/journal.pone.0010436 ↗
64. 10.1084/jem.2004113010.1084/jem.20041130 ↗
65. 10.1080/2162402X.2015.105129710.1080/2162402X.2015.1051297 ↗
66. 10.1186/1479-5876-12-3610.1186/1479-5876-12-36 ↗
67. 10.1172/JCI3117810.1172/JCI31178 ↗
68. 10.1016/j.coph.2017.05.00210.1016/j.coph.2017.05.002 ↗
69. 10.1016/j.celrep.2015.08.07710.1016/j.celrep.2015.08.077 ↗
70. 10.1016/j.ejca.2017.01.01110.1016/j.ejca.2017.01.011 ↗
71. 10.1186/s40425-015-0094-910.1186/s40425-015-0094-9 ↗
72. 10.1158/1078-0432.CCR-14-051410.1158/1078-0432.CCR-14-0514 ↗
73. 10.1158/1078-0432.CCR-15-302610.1158/1078-0432.CCR-15-3026 ↗
74. 10.1158/0008-5472.CAN-09-310910.1158/0008-5472.CAN-09-3109 ↗
75. 10.1038/onc.2010.29210.1038/onc.2010.292 ↗
76. 10.1182/blood-2007-03-08164610.1182/blood-2007-03-081646 ↗
77. 10.1038/nrd263810.1038/nrd2638 ↗
78. 10.1073/pnas.090880110710.1073/pnas.0908801107 ↗
79. 10.1158/0008-5472.CAN-14-095710.1158/0008-5472.CAN-14-0957 ↗
80. 10.1016/j.neo.2017.02.00410.1016/j.neo.2017.02.004 ↗
81. 10.1016/j.coph.2016.06.00910.1016/j.coph.2016.06.009 ↗
82. 10.1016/j.ejca.2017.02.01310.1016/j.ejca.2017.02.013 ↗
83. 10.1002/cam4.233210.1002/cam4.2332 ↗
84. 10.1016/j.it.2017.12.00510.1016/j.it.2017.12.005 ↗
85. 10.3892/or.2012.183110.3892/or.2012.1831 ↗
86. 10.1158/1078-0432.CCR-04-146910.1158/1078-0432.CCR-04-1469 ↗
87. 10.3727/096504017X1490050502089510.3727/096504017X14900505020895 ↗
88. 10.1038/nri.2017.4910.1038/nri.2017.49 ↗
89. 10.1007/BF0019921410.1007/BF00199214 ↗
90. 10.1016/S0092-8674(00)80856-910.1016/S0092-8674(00)80856-9 ↗
91. 10.1034/j.1600-065X.2001.1820104.x10.1034/j.1600-065X.2001.1820104.x ↗
92. 10.1073/pnas.20036309710.1073/pnas.200363097 ↗
93. 10.1084/jem.191.5.77110.1084/jem.191.5.771 ↗
94. 10.1158/1078-0432.CCR-17-245110.1158/1078-0432.CCR-17-2451 ↗
95. Li Q. · Cancer Res. · 2005 · 65 · 106310.1158/0008-5472.1063.65.3 ↗
96. 10.1016/S0264-410X(02)00032-410.1016/S0264-410X(02)00032-4 ↗
97. Zitvogel L. · J. Immunol. · 1995 · 155 · 139310.4049/jimmunol.155.3.1393 ↗
98. 10.1200/JCO.2001.19.18.383610.1200/JCO.2001.19.18.3836 ↗
99. 10.1016/j.jhep.2017.04.02010.1016/j.jhep.2017.04.020 ↗
100. 10.1200/JCO.2016.68.110610.1200/JCO.2016.68.1106 ↗